'DTx' SRPA, Seeking Global Commercialization of 'Pediatric Myopia DTx' in Singapore

Digital health company SRP Therapeutics announced on the 29th that it participated in the Ventureblick Global Healthcare Specialized Acceleration Program held in Singapore.

Im Chan-ho, Chief Business Officer of SRP Therapeutics, is presenting at the Ventureblick Global Healthcare Specialized Acceleration Program held in Singapore.
[Photo by SRP Therapeutics]

SRP was selected in May as part of the Ministry of SMEs and Startups' Super-gap Startup 1000+ (DIPS 1000+) in the bio-health sector, which led to its participation in this global accelerator program. The event, held from the 23rd to the 26th, was hosted by HealthTEC.SG, a consortium under the Agency for Science, Technology and Research (A-STAR) of Singapore, a partner of Ventureblick, a company specializing in healthcare incubation.

SRP used this event as an opportunity to explore global commercialization strategies for its main pipelines, SAT-001 and SAT-014. Singapore is regarded as a strategic gateway for Asian companies expanding overseas and a medical hub. The company stated, "We experienced the local industrial ecosystem in Singapore, designed global expansion plans including overseas regulatory approvals, and acquired investment attraction strategies," adding, "We also gained opportunities for business networking and to showcase each company's capabilities."

SRP is pursuing overseas expansion based on various digital therapeutic (DTx) specialized technologies. SAT-001, a DTx for pediatric myopia treatment currently undergoing confirmatory clinical trials in Korea, was licensed out in March to Japan’s Rohto Pharmaceutical for Japan and some Asian regions. Rohto Pharmaceutical also made a strategic investment (SI) in SRP. SRP is also developing SAT-014, a therapeutic trial software medical device aimed at alleviating symptoms of adjustment disorder and post-traumatic stress disorder (PTSD) such as depression and anxiety following stress and psychological trauma. As a cognitive therapy trial software, it received clinical trial approval (IND) from the Ministry of Food and Drug Safety in September last year and is currently conducting exploratory clinical trials.

Im Chan-ho, SRP’s Chief Business Officer who attended the event, said, “It was a meaningful opportunity to glimpse the expectations for DTx, which is regarded as the ‘third new drug,’” and added, “It was a learning platform for reviewing strategies for the successful commercialization of core products such as SAT-014 and for enhancing technological capabilities.”

This content was produced with the assistance of AI translation services.